The U.S. Food and Drug Administration has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Both Sanofi and AstraZenica plan to make Beyfortus available in the U.S. ahead of the upcoming 2023-2024 RSV season.
NCPA
